DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20163416
Published: 2016-12-15

Depot-medroxy progesterone acetate as an effective contraception method in lactating mothers

Vijaya Monish Babre, Jyaneshwari Ashok Phadke

Abstract


Background: Contraception is the deliberate use of artificial methods or other techniques to prevent pregnancy as a consequence of sexual intercourse. Depot medroxy progesterone (DMPA) injection 150 mg intramuscular was used for contraception in this study, once every 3 months±14 days. The objective was to establish safety and effectiveness of DMPA in lactating and non-lactating mothers, observe side effects related to usage of DMPA and also establish its effectiveness as contraception method.

Methods: This is retrospective study performed at Family Planning Association of India’s Kutumb Sudhar Kendra. Mumbai Central.

Result: Patients who had received first dose at 6 weeks of postpartum period and those who received between 6 weeks to one year showed lactation in 84.16% and non-lactation in 15.84%. 28.71% lactating patients had taken injection at 6 weeks of post-partum period and 71.29% had taken between 6 weeks to 1 year. Lactating patients who had taken injection at 6 weeks and continued DMPA for more than 4 injections were 48.27%. 36.84% non-lactating patients had continued for more than 4 injections. This signifies that acceptance and continuation rate of DMPA is more in lactating patients than in non-lactating patients.

Conclusions: DMPA is an effective method of contraception in lactating mothers; proper counseling will increase awareness and acceptance of DMPA in lactating mothers.


Keywords


Injection DMPA, Contraceptive method, Lactating mother

Full Text:

PDF

References


Family planning Queenland. Available at https://en.wikipedia.org/wiki/Family_Planning_Queensland. Accessed on 3 February 2011.

Chaudhri SK and International Contributors. Practice of Fertility Control: A Comprehensive Textbook. 4th edition, 2000.

Sengupta J. Accessing modern contraceptive technologies in India. Indian J Physiol Pharmacol. 2006;50(4):327-40.

Kaunitz AM. Current options for injectable contraception in the United States. Semin Reprod Med. 2001;19(4):331-7.

Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, et al. Depo provera position paper on clinical use, effectiveness and side effects. Br J Fam Plann. 1999;25(2):69-76.

WHO collaborative study of neoplasia and steroid contraceptives. Depot-medroxy progesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer. 1999;49(2):186-90.

Santen, Richard J. Endocrinology of breast and endometrial cancer. In Strauss, Jerome F. Barbieri, Robert L. Yen and Jaffe's Reproductive Endocrinology. 5th edition; Philadelphia:Elsevier Saunders. 2004:787-809.

Westhoff C. Depot-medroxyprogesterone acetate injection (depot-provera): a highly effective contraceptive option with proven long-term safely. Contraception. 2003;68(2):75-87.

Leon S, Darney Philip D. Injectable contraception. In: Speroff Leon, Darney Philip D, eds. A Clinical Guide for Contraception. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2005: 201-220.

Obrien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia. 2006;47(9):1419-22.